From Source to Submission: A Look into the Emerging Clinical Research as a Care Option—An Interview with Elligo Health Research CEO John Potthoff

From Source to Submission A Look into the Emerging Clinical Research as a Care Option An Interview with Elligo Health Research CEO John Potthoff

Recently, TrialSite covered an important investment placed by one of the top electronic health record vendors in North America. Cerner, a Kansas City-based medical technology market leader recently made a strategic investment in clinical research as a care option (CRAACO) leader Elligo Health Research (Elligo).  In “Clinical Research as a Care Option Just Got More Interesting with Leading EHR Vendor Investing in Elligo Health Research,” TrialSite noted at some point in the United States and beyond, that research and the clinic will meld in heretofore not feasible ways. Fortunately for TrialSite as well as for those interested in how this coming together of research and the clinic is evolving, Elligo’s CEO John Potthoff joined TrialSite’s founder Daniel O’Connor for a brief but impactful interview.  After all, Elligo has been at the forefront of the movement to bring together research and healthcare in North America.

An Impressive Professional

Mr. Potthoff impressed TrialSite’s O’Connor with an intellectually-charged, yet pragmatic industry depth, impressive professional acumen, adeptness and flexibility, and a certain kind of emotional intelligence that when combined most ce...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee